NXTC
NXTC clinical trials: NextCure, Inc.
Every trial on ClinicalTrials.gov where NextCure, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 7
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NXTC on the catalyst calendar · NXTC registry changes
- Primary completion Feb 2028Sponsor estimatePhase 1NCT06792552A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNextCure, Inc. · Advanced Solid TumorsRecruitingNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualPhase 1/Phase 2NCT05572684A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNextCure, Inc. · Advanced or Metastatic Solid TumorsTerminatedNXTCLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 1NCT05787496A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsNextCure, Inc. · Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2024ActualPhase 1/Phase 2NCT04875806A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsNextCure, Inc. · Advanced or Metastatic Solid TumorsTerminatedNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 6, 2023ActualPhase 1/Phase 2NCT04408599A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid TumorsNextCure, Inc. · Advanced or Metastatic Solid TumorsTerminatedNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2023ActualPhase 1/Phase 2NCT03665285A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNextCure, Inc. · Advanced or Metastatic Solid TumorsCompletedNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2022Sponsor estimatePhase 1/Phase 2NCT04430933A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCNextCure, Inc. · Advanced or Metastatic Solid TumorsWithdrawnNXTCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT04699123The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerYale University · Advanced Non-small Cell Lung CancerActive, not recruitingNXTCCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT06941857NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Pancreatic CancerRecruitingNXTCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner